Does Cosentyx Affect Female Fertility?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no evidence of impairing female fertility in animal studies or human data. Clinical trials and post-marketing reports do not indicate fertility risks for women of childbearing potential. Women are advised to use effective contraception during treatment and for up to 20 weeks after the last dose due to potential fetal harm, not fertility issues.[1][2]
What Do Animal Studies Say?
In female rats and cynomolgus monkeys, secukinumab had no adverse effects on fertility, estrus cycles, or reproductive performance at doses up to 12 times the human equivalent. No embryotoxicity linked to fertility was observed.[2]
Any Reports from Human Trials or Real-World Use?
Phase 3 trials excluded pregnant women and did not assess fertility endpoints directly. No fertility impairments emerged in exposed women. Pregnancy registries and FDA labeling confirm no fertility signals, though data on conception post-treatment remains limited.[1][3]
Can Women Planning Pregnancy Use Cosentyx?
Discontinue Cosentyx before trying to conceive, allowing 20 weeks for clearance (half-life ~27 days). Live vaccines are contraindicated during treatment and for varying periods after.[1][2] Consult a doctor for personalized timing.
Male Fertility Concerns with Cosentyx?
No impact on male fertility in animal studies or humans; sperm parameters remained normal.[2]
Sources
[1]: FDA Cosentyx Label
[2]: Cosentyx Prescribing Information
[3]: Drugs.com - Cosentyx Fertility